These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 3830780)

  • 1. [Preliminary evaluation of the pharmacokinetics and toxicity of esorubicin].
    Piazza E; Negretto E; Vago G; Pacciarini MA; Tamassia V
    G Ital Chemioter; 1985; 32(1):21-4. PubMed ID: 3830780
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II trial of esorubicin in patients with advanced colorectal carcinoma.
    Fiore J; Kemeny N; Raymond V; Young C
    Cancer Treat Rep; 1986 Oct; 70(10):1241-2. PubMed ID: 3530453
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacokinetics of liposomal doxorubicin (TLC-D99; Myocet) in patients with solid tumors: an open-label, single-dose study.
    Mross K; Niemann B; Massing U; Drevs J; Unger C; Bhamra R; Swenson CE
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):514-24. PubMed ID: 15322827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of esorubicin (4'deoxydoxorubicin, DxDx) in patients with small cell lung cancer.
    Rigas JR; Kris MG; Gralla RJ; Heelan RT; Marks LD
    Invest New Drugs; 1991 May; 9(2):187-90. PubMed ID: 1651908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II evaluation of esorubicin in ovarian cancer. A Southwest Oncology Group study.
    Alberts DS; Mason-Liddil N; Stock-Novack D; O'Toole RV; Abbott TM; Salmon SE
    Am J Clin Oncol; 1992 Apr; 15(2):146-9. PubMed ID: 1553903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and metabolism of pirarubicin in humans: correlation with pharmacodynamics.
    Marchiset-Leca D; Leca FR; Galeani A; Noble A; Catalin J
    Cancer Chemother Pharmacol; 1995; 36(3):239-43. PubMed ID: 7781145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of weekly low-dose 4'-epi-doxorubicin in advanced postmenopausal breast cancer.
    Jones WG; Mattsson W
    Cancer Treat Rep; 1984 Apr; 68(4):675-7. PubMed ID: 6585271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of esorubicin (4' deoxydoxorubicin) in cancers of the breast, colon, kidney, lung and melanoma.
    Braich TA; Salmon SE; Robertone A; Alberts DS; Jones SE; Miller TP; Garewal HS
    Invest New Drugs; 1986; 4(3):269-74. PubMed ID: 3818231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiotoxicity associated with 4'-deoxydoxorubicin.
    Blayney D
    Cancer Treat Rep; 1986 Mar; 70(3):433. PubMed ID: 3955560
    [No Abstract]   [Full Text] [Related]  

  • 10. [Pharmacokinetics and acute signs of cardiac toxicity during doxorubicin therapy].
    Lenzhofer R; Schneeweiss B; Rameis H; Eichler H; Graninger W; Dittrich C; Dudczak R; Ganzinger U; Gasic S; Moser K
    Wien Klin Wochenschr; 1983 Jan; 95(2):52-5. PubMed ID: 6858169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study.
    Vaughn CB; Salmon SE; Fleming TR
    Invest New Drugs; 1990 Feb; 8(1):81-5. PubMed ID: 2188929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.
    Fokkema E; Verweij J; van Oosterom AT; Uges DR; Spinelli R; Valota O; de Vries EG; Groen HJ
    Br J Cancer; 2000 Feb; 82(4):767-71. PubMed ID: 10732743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New anthracyclines in the treatment of solid tumors in the advanced stage].
    Pannuti F; Martoni A; Lelli G; Camaggi CM; Strocchi E; Fruet F
    G Ital Chemioter; 1985; 32(1):49-56. PubMed ID: 3868636
    [No Abstract]   [Full Text] [Related]  

  • 14. Esorubicin in advanced endometrial cancer: an ineffective and potentially toxic therapy. A Southwest Oncology Group study.
    Green JB; Green S; O'Toole RV; Alberts DS; Nahhas WA; Wallace DL
    Invest New Drugs; 1991 May; 9(2):191-3. PubMed ID: 1874602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Penile ulceration during pegylated doxorubicin chemotherapy of classical Kaposi's sarcoma.
    Cannavò SP; Borgia F; Scimone A; Guarneri B
    Acta Derm Venereol; 2009; 89(2):216-7. PubMed ID: 19326025
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparative pharmacokinetics and metabolism of doxorubicin and epirubicin in patients with metastatic breast cancer.
    Robert J; Vrignaud P; Nguyen-Ngoc T; Iliadis A; Mauriac L; Hurteloup P
    Cancer Treat Rep; 1985 Jun; 69(6):633-40. PubMed ID: 3893693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of esorubicin in patients with advanced melanoma.
    Frustaci S; Gasparini G; Galligioni E; Tirelli U; Di Pietro N; Crivellari D; Lo Re G; Monfardini S
    Cancer Treat Rep; 1987 Mar; 71(3):325-6. PubMed ID: 3815399
    [No Abstract]   [Full Text] [Related]  

  • 18. The liposomal formulation of doxorubicin.
    Abraham SA; Waterhouse DN; Mayer LD; Cullis PR; Madden TD; Bally MB
    Methods Enzymol; 2005; 391():71-97. PubMed ID: 15721375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human pharmacokinetics of esorubicin (4'-deoxydoxorubicin).
    Dodion P; Davis TA; Rozencweig M; Crespeigne N; Kenis Y; Bachur NR
    Invest New Drugs; 1985; 3(4):361-8. PubMed ID: 4086243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of liver metastases on the pharmacokinetics of doxorubicin---a population-based pharmacokinetic project of the CESAR-APOH.
    Müller HJ; Port RE; Grubert M; Hilger RA; Scheulen M; Mross K;
    Int J Clin Pharmacol Ther; 2003 Dec; 41(12):598-9. PubMed ID: 14692710
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.